Clinical Trial Update: Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation study of AZD1775 with gemcitabine and radiation for unresectable pancreatic adenocarcinoma completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• AZD1775 (Adavosertib)
• Gemcitabine (Gemcitabine)
• Radiation therapy

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Adenocarcinoma of the Pancreas | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-17